IM IMRN Immuron Limited American Depositary Shares (ADR) Loading... : Investor Sentiment and Bull/Bear Views

The author argues IMRN is the next big biotech runner due to huge backing from the military and Department of Defense, with ongoing research relationships with major US military institutions. Catalysts cited include an imminent ProIBS launch (originally scheduled for Q4) and a phase 2 clinical trial for IMM-200 in the first half of 2026. The author also notes no dilution with cash for the next year and a large gap to fill on the daily chart from a 52-week high of $2.50 versus the current $1.00.

The author argues IMRN is a pharmaceutical play with huge backing from the military and Department of Defense and ongoing research relationships with major US military institutions. Catalysts cited are the planned launch of ProIBS any day now (originally scheduled for Q4) and initiation of a Phase 2 clinical trial for IMM-200 in the first half of 2026. The author also notes no dilution with cash for the next year and a 52-week high of 2.50 versus a current 1.00 with a gap to fill on the daily chart.

The author argues IMRN has bottomed as a low-float biotech with huge backing from the military and Department of Defense and ongoing research relationships with major US military institutions. Catalysts cited are the imminent launch of ProIBS (originally scheduled for Q4) and initiation of a Phase 2 trial for IMM-200 in the first half of 2026, with no dilution and cash for the next year. The stock sits at $1.00 versus a 52-week high of $2.50, leaving a large daily-chart gap the author expects to be filled.

The author claims IMRN is a bottomed-out biotech play with huge backing from the military and Department of Defense, supported by ongoing research relationships with major US military institutions. The stated catalysts are the imminent launch of ProIBS (originally scheduled for Q4) and the initiation of a Phase 2 clinical trial for IMM-200 during the first half of 2026. The author frames these events as drivers of a potential 'next big biotech runner.'

The author argues IMRN is a bottomed low-float pharmaceutical play with huge backing from the military and Department of Defense, and ongoing research relationships with major US military institutions. He cites upcoming catalysts: the planned launch of ProIBS any day now (originally scheduled for Q4) and the initiation of a phase 2 clinical trial for IMM-200 in the first half of 2026. He also notes no dilution with cash for the next year and a large gap to fill on the daily chart from a 52-week high of $2.50 down to $1.00.

The author argues IMRN is a bottomed low-float biotech with huge backing from the military and Department of Defense, and ongoing research relationships with major US military institutions. Catalysts include the imminent launch of ProIBS (originally scheduled for Q4) and initiation of a Phase 2 trial for IMM-200 in the first half of 2026. The author notes no dilution with cash for the next year and a large gap to fill on the daily chart toward the 52-week high of $2.50 from the current $1.00.

The author argues IMRN is a bottomed-out biotech with strong backing from the military and Department of Defense, supported by ongoing research relationships with major US military institutions. The stated catalysts are the imminent launch of ProIBS (originally scheduled for Q4) and the initiation of a Phase 2 clinical trial for IMM-200 in the first half of 2026. No specific risk is stated.